Chemours (CC) Earnings Date, Estimates & Call Transcripts $20.89 -0.21 (-1.00%) (As of 02:29 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Chemours Latest Earnings SummaryActual EPS (Nov. 4) $0.40 Beat By $0.08 Consensus EPS (Nov. 4) $0.32 Chemours released Q3 2024 earnings on November 4, 2024, reporting an EPS of $0.40, which topped the consensus estimate of $0.32 by $0.08. Quarterly revenue rose .9% year-over-year to $1.50 billion, above the consensus estimate of $1.44 billion. With a trailing EPS of $0.50 and a P/E Ratio of 41.78, Chemours' earnings are expected to grow 57.04% next year, from $1.35 to $2.12 per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckPowered by Get Chemours Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemours and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThe case for Joe BidenA few months back, Biden signed a bill aimed at accelerating a radical technology your average investor finds too controversial to touch… But that people like Bill Gates, Jeff Bezos, Peter Thiel, Sam Altman, and Warren Buffett are all investing hundreds of millions in.Click here to discover why this company is the real winner. Chemours Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20241$0.38$0.38$0.38 Q2 20241$0.80$0.80$0.80 Q3 20241$0.38$0.38$0.38 Q4 20241$0.18$0.18$0.18 FY 20244$1.74$1.74$1.74 Q1 20251$0.57$0.57$0.57 Q2 20251$0.79$0.79$0.79 Q3 20251$0.61$0.61$0.61 Q4 20251$0.43$0.43$0.43 FY 20254$2.40$2.40$2.40 Q1 20261$0.60$0.60$0.60 Q2 20261$0.81$0.81$0.81 Chemours Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/4/2024Q3 2024$0.32$0.40+$0.08$0.98$1.44B$1.50B8/1/2024Q2 2024$0.57$0.38 -$0.19$0.30$1.53B$1.54B4/30/2024Q1 2024$0.25$0.32+$0.07$0.30$1.35B$1.35B3/27/2024Q4 2023$0.29$0.31+$0.02$0.74$1.37B$1.36B10/26/2023Q3 2023$0.77$0.64 -$0.13$1.15$1.54B$1.49B7/28/2023Q2 2023$1.09$1.10+$0.01$4.72$1.75B$1.64B Get the Latest News and Ratings for CC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Chemours and its competitors with MarketBeat's FREE daily newsletter. 4/28/2023Q1 2023$0.62$0.98+$0.36$1.00$1.46B$1.54B2/10/2023Q4 2022$0.15$0.08 -$0.07$0.64$1.27B$1.34B Chemours Earnings - Frequently Asked Questions When did Chemours announce their last quarterly earnings? Chemours (NYSE:CC) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on CC's earnings history. Did Chemours beat their earnings estimates last quarter? In the previous quarter, Chemours (NYSE:CC) reported $0.40 earnings per share (EPS) to beat the analysts' consensus estimate of $0.32 by $0.08. Learn more on analysts' earnings estimate vs. CC's actual earnings. How can I listen to Chemours's earnings conference call? The conference call for Chemours's latest earnings report can be listened to online. Listen to Conference Call How can I read Chemours's conference call transcript? The conference call transcript for Chemours's latest earnings report can be read online. Read Transcript How much revenue does Chemours generate each year? Chemours (NYSE:CC) has a recorded annual revenue of $6.03 billion. How much profit does Chemours generate each year? Chemours (NYSE:CC) has a recorded net income of -$238 million. CC has generated $0.50 earnings per share over the last four quarters. What is Chemours's price-to-earnings ratio? Chemours (NYSE:CC) has a trailing price-to-earnings ratio of 41.78 and a forward price-to-earnings ratio of 15.47. What is Chemours's EPS forecast for next year? Chemours's earnings are expected to grow from $1.35 per share to $2.12 per share in the next year, which is a 57.04% increase. More Earnings Resources from MarketBeat Related Companies AXTA Earnings CSWI Earnings ESI Earnings ICL Earnings ALTM Earnings MEOH Earnings PCT Earnings TROX Earnings PRM Earnings NGVT Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report The case for Joe Biden (Ad)A few months back, Biden signed a bill aimed at accelerating a radical technology your average investor finds too controversial to touch… But that people like Bill Gates, Jeff Bezos, Peter Thiel, Sam Altman, and Warren Buffett are all investing hundreds of millions in.Click here to discover why this company is the real winner. This page (NYSE:CC) was last updated on 12/6/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon declares war on company he co-founded!?Elon Musk is leading humanity into the new era of AI. He’s just received a fresh $6 billion in funding for ...Porter & Company | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredThis Company is Helping Brands Go Digital with Innovative Solutions.The growth of social media, e-Commerce, AI adoption and digital transformation has created an enormous window ...Huge Alerts | SponsoredVanguard issues correction warningThe S&P just notched another record close... Apple and Meta are leading the Nasdaq to extraordinary new hei...Chaikin Analytics | SponsoredThe Biggest Financial Event of 2024?Should you buy, sell, or hold your stock? To find the answer, let’s look at the actions of the world’s weal...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Chemours Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemours With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.